June 16, 2025 (PharmaBiz) –
Chrysalis, a GMP-ready space and service provider, officially launches following the acquisition of facility assets from
With facilities in
“Our model is particularly valuable for programs where retaining process control, protecting IP, and minimizing risk are crucial considerations,” said
“Our approach gives our customers flexibility to take only the space and services they need, when they need it. By providing rapid access to GMP-compliant space and operational support, we empower our customers to advance on their own terms, transforming scientific promise into real progress without the burden of scheduling constraints or unnecessary ongoing expense.”
With entry to cleanroom times as short as four to six weeks, Chrysalis offers tailored, cleanroom environments on flexible terms. This allows clients to flex manufacturing activities in line with their project needs and milestones, minimizing expenditure while maximizing control.
Chrysalis partners with a wide spectrum of life science clients, from early-stage biotech companies to top 10 pharmaceutical firms, contract research organizations (CROs), and other life science stakeholders by providing fit-for-purpose space in key US innovation hubs. Its facilities accommodate a wide array of therapeutic modalities and technical needs, helping clients maintain control and adapt quickly as their programmes evolve.
Sarah added: “Whether clients are navigating early development or preparing for commercialization, we’re here to grow with them. We don’t just provide space, we build partnerships grounded in collaborative operational excellence and a deep understanding of what it takes to operate in a GMP environment.”
Chrysalis is positioned to scale rapidly, enhance its infrastructure, expand into additional geographies, and extend its service offerings to meet the growing demand for agile manufacturing solutions.
Chrysalis was built to solve the problems that hold many promising programmes back: manufacturing delays, limited flexibility and a lack of control.
Chrysalis offers something different: a home where therapeutic innovations have space to transform.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.